Innovative pharmaceutical enterprises are more competitive under the epidemic situation

What enlightenment does the new outbreak bring to pharmaceutical enterprises? How will it affect the follow-up development of pharmaceutical enterprises? Innovation is still the short board of traditional pharmaceutical companies "This big test of the epidemic seems to reveal that the innovation ability of traditional pharmaceutical companies needs to be improved" - in a conversation with cypress blue, an insider expressed the above views Novel coronavirus pneumonia is China's most popular novel coronavirus pneumonia, such as the sixth edition of the new crown pneumonia treatment plan mentioned by RP / ritonavir, Leigh Bhave Lin, Al IBE, chloroquine phosphate, and widely concerned Reed, Fa Pilar Vee and so on Chinese pharmaceutical companies are more often seen in the role of fast copycat At present, Coriolis (lopinavir / litonavir) is supplied by the original research and development pharmaceutical company ebev, and the domestic pharmaceutical company Kelun Pharmaceutical Co., Ltd announced that it has successfully imitated it, and it can achieve mass production in March The novel coronavirus pneumonia, known as the "first" approved pneumonia treatment in China, is actually a generic drug, actually, according to the chairman of the Oriental biotic medicine Polytron Technologies Inc Radcivir of Gilead is still in clinical trials Borui biology and Hainan Haiyao announced that they could be mass-produced and imitated, but they could not jump out of the circle of imitations In this outbreak, many pharmaceutical enterprises have actively participated in the prevention and treatment of the epidemic, produced a large number of related drugs (including traditional Chinese Medicine), and made a lot of contributions But we need to face up to the fact that most of the existing drugs are adjuvant drugs, such as improving patients' immunity, promoting rehabilitation and so on The real specific drugs for the virus have not been found, and the research and development of related vaccines are also driven by innovative bio pharmaceutical companies, which highlights that the research and development capacity of traditional pharmaceutical companies is indeed very limited - Qiu said to cypress blue Zhongcheng international also pointed out that the outbreak exposed the shortage of medical materials in China in emergency situations, the long time of research and development of therapeutic drugs, the dependence on foreign original research and drug support and other problems China will strengthen the medical material reserve, continuously increase investment in the medical industry, encourage pharmaceutical enterprises to expand research and development expenditure and improve innovation ability, so as to improve the pharmaceutical industry in China Competitiveness "In my opinion, in the long run, the state needs to further increase its support for innovative pharmaceutical enterprises to build China's own new drug research and development capabilities," said Qiu "This epidemic has led to the suspension of many hospitals except fever clinics On the one hand, many patients suffering from other diseases can not be treated in time, on the other hand, many pharmaceutical companies' products will also be unsalable, and it is estimated that most pharmaceutical companies' first quarter statements will be ugly, "Qiu said to saberland In addition, in order to deal with the epidemic situation, the state health insurance bureau and the Ministry of Finance issued an emergency notice - for the medical expenses incurred by patients, after the basic medical insurance, serious illness insurance, medical assistance, etc are paid according to the regulations, the personal burden part will be subsidized by the finance In addition, the novel coronavirus policy has been introduced to the National Health Council's "new coronavirus pneumonia diagnosis and treatment plan" covering drugs and medical services, which are temporarily included in the payment scope of the medical insurance fund Some analysts pointed out that the income and growth rate of medical insurance fund are limited If the expenditure in the first half of the year is too large, after the epidemic in the second half of the year, the efforts of medical insurance fee control may increase, and the drug price may face further reduction In the face of the superposed effect of the new crown epidemic, CIC analysis points out that in the long run, pharmaceutical manufacturing enterprises with obvious competitive advantages in core products, diversified products and outstanding R & D capabilities and pharmaceutical distribution enterprises with perfect distribution network layout and channel construction will maintain stronger competitive advantages and anti risk capabilities In addition, fan Yichao, executive director of Shengshan assets, told saibelan, "we found that one of the common concerns of enterprises is that the financing environment will become more difficult this year." Fan Yichao further said that this year, cash is indeed the king No matter the investment company or the start-up company, whoever has enough cash in his hand will win more The epidemic will bring greater challenges to enterprises, but the strong will always be strong, which may speed up the emergence of a number of top enterprises A butterfly fluttering its wings can still cause a hurricane Pharmaceutical companies should not be unprepared for such large emergencies as the new crown epidemic Fan Yichao believes that cash is the king, pharmaceutical companies should treasure bullets, make the most efficient use of funds, ensure that the cash on account can support more than half a year, and always maintain the sensitivity of financing She also told saibelan that pharmaceutical companies should be bold in innovation, and only by accumulating can they have thin hair - in addition to the new technologies such as mRNA vaccine, which are widely concerned in this epidemic, some technologies worthy of attention also include protac, bispecific antibody platform, single cell sequencing technology, cell and gene therapy, oncolytic drugs and so on Always be prepared to stand out in the critical moment.